ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Start-up Entasis has hefty funding round

by Lisa M. Jarvis
April 11, 2016 | APPEARED IN VOLUME 94, ISSUE 15

The antibiotics start-up Entasis Therapeutics has raised $50 million in its second round of financing. Entasis was spun off from AstraZeneca in early 2015 after the big pharma firm failed to find a buyer for the unit. AstraZeneca initially committed up to $40 million to the new company; this next funding round, from outside firms, will help support Entasis’s most advanced drug candidate, ETX0914, a gyrase inhibitor in Phase II studies to treat gonorrhea.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment